Compositions comprising oligosaccharides

Abstract

The present invention concerns compositions comprising a saccharide for the inhibition of pathogen adhesion to mammalian cells.

1 - 31 . (canceled) 
     
     
         32 . A nutritional or pharmaceutical composition for the inhibition of pathogenic bacteria adhesion to mammalian cells, or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, wherein the mammal cells invaded or infected are mammalian gut or intestinal epithelial cells, the composition comprising:
 a first compound comprising a therapeutically effective amount of caseinoglycomacropeptides (CGMP); and   a second compound comprising proanthocyanidins.   
     
     
         33 . The nutritional or pharmaceutical composition according to  claim 32 , wherein the therapeutically effective amount of the compound is between about 1 g and about 15 g. 
     
     
         34 . The nutritional or pharmaceutical composition according to  claim 32 , wherein the composition comprises a caloric content of less than about 1000 kcal. 
     
     
         35 . The nutritional or pharmaceutical composition according to  claim 32 , wherein the composition further comprises partially hydrolysed guar gum. 
     
     
         36 . A nutritional or pharmaceutical composition for the treatment of acute or chronic pathogenic bacteria-associated enteric disorders in a mammal, or for the treatment of pathogenic bacteria microflora proliferation in a mammal, the composition comprising:
 a first compound comprising a therapeutically effective amount of caseinoglycomacropeptides (CGMP); and   a second compound comprising proanthocyanidins.   
     
     
         37 . The nutritional or pharmaceutical composition according to  claim 36 , wherein said acute or chronic pathogenic bacteria-associated enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof. 
     
     
         38 . A method for inhibiting pathogenic bacteria adhesion to mammalian cells or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, the method comprising administering to a mammal a composition comprising:
 a first compound comprising a therapeutically effective amount of caseinoglycomacropeptides (CGMP); and   a second compound comprising proanthocyanidins.   
     
     
         39 . A method of treating acute or chronic pathogenic bacteria-associated, enteric disorders in a mammal, said method comprising administering to said mammal a composition comprising. a therapeutically effective amount of caseinoglycomacropeptides (CGMP). 
     
     
         40 . The method according to  claim 39 , wherein said enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof. 
     
     
         41 . The method according to  claim 39 , wherein the composition further comprises a therapeutically effect amount of partially hydrolysed guar gum. 
     
     
         42 . A method for the manufacture of a nutritional or pharmaceutical composition for the inhibition of pathogenic bacteria adhesion to mammalian cells, or for reducing or inhibiting the invasion and infection of mammalian cells by pathogenic bacteria, the method comprising adding to the nutritional or pharmaceutical composition a first compound comprising a therapeutically effective amount of caseinoglycomacropeptides (CGMP); and
 a second compound comprising proanthocyanidins.   
     
     
         43 . The nutritional or pharmaceutical composition according to  claim 42 , wherein the therapeutically effective amount of the compound is between about 1 g and about 15 g. 
     
     
         44 . The nutritional or pharmaceutical composition according to  claim 42 , wherein the composition comprises a caloric content of less than about 1000 kcal. 
     
     
         45 . A method for the manufacture of a nutritional or pharmaceutical composition for the treatment of acute or chronic pathogenic bacteria-associated enteric disorders in a mammal or for the treatment of pathogenic bacteria microflora proliferation in the mammal, the method comprising adding to the nutritional or pharmaceutical composition a first compound comprising a therapeutically effective amount of caseinoglycomacropeptides (CGMP); and
 a second compound comprising proanthocyanidins.   
     
     
         46 . The nutritional or pharmaceutical composition according to  claim 45 , wherein the therapeutically effective amount of the compound is between about 1 g and about 15 g. 
     
     
         47 . The nutritional or pharmaceutical composition according to  claim 45 , wherein the composition comprises a caloric content of less than about 1000 kcal. 
     
     
         48 . A method according to  claim 45 , wherein said enteric disorders are selected from the group consisting of gastroenteritis, ulcerative colitis, diarrhoeal diseases, and combinations thereof.